November 24, 2014 | The Israeli biopharmaceutical company developing a universal influenza vaccine, BiondVax, is considering a Wall Street IPO, according to a “Globes” report. The company currently has a market cap of NIS 42 million (approx. $10.8 million) on the Tel Aviv Stock Exchange, which it hopes to maintain in a potential American offering. BiondVax’s universal flu vaccine, to treat a number of prominent flu strains, has already undergone a successful Phase II clinical trial and further trials will take place in 2015. BiondVax was founded in 2003 by its CEO Ron Babecoff.